State of New Jersey Common Pension Fund D Sells 1,793 Shares of Hologic, Inc. (NASDAQ:HOLX)

State of New Jersey Common Pension Fund D reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,162 shares of the medical equipment provider’s stock after selling 1,793 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.06% of Hologic worth $9,300,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Stevens Capital Management LP bought a new position in shares of Hologic in the 4th quarter worth $806,000. Meritage Portfolio Management lifted its holdings in shares of Hologic by 6.6% in the 4th quarter. Meritage Portfolio Management now owns 141,485 shares of the medical equipment provider’s stock worth $10,109,000 after purchasing an additional 8,806 shares in the last quarter. Corbyn Investment Management Inc. MD bought a new position in shares of Hologic in the 4th quarter worth $247,000. GAMMA Investing LLC bought a new position in shares of Hologic in the 4th quarter worth $155,000. Finally, California Public Employees Retirement System lifted its holdings in shares of Hologic by 2.0% in the 4th quarter. California Public Employees Retirement System now owns 1,422,317 shares of the medical equipment provider’s stock worth $101,625,000 after purchasing an additional 27,461 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of Hologic stock traded down $1.00 during trading hours on Thursday, hitting $75.71. 1,190,936 shares of the company’s stock traded hands, compared to its average volume of 1,779,627. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $87.88. The stock has a market capitalization of $17.77 billion, a price-to-earnings ratio of 36.36, a PEG ratio of 2.61 and a beta of 1.00. The company has a fifty day simple moving average of $75.95 and a 200-day simple moving average of $72.72. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. During the same period last year, the firm posted $1.07 EPS. The business’s revenue was down 5.7% compared to the same quarter last year. Equities research analysts anticipate that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. UBS Group raised their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. William Blair restated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Wednesday, April 10th. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Finally, Evercore ISI raised their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $87.00.

Insider Buying and Selling

In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,846 shares of company stock valued at $2,473,443. 1.75% of the stock is owned by insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.